


## PHARMACEUTICAL 2019

## UroGen Pharma Ltd. Rank 139 of 363









## PHARMACEUTICAL 2019

## UroGen Pharma Ltd. Rank 139 of 363



The relative strengths and weaknesses of UroGen Pharma Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UroGen Pharma Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 106% points. The greatest weakness of UroGen Pharma Ltd. is the variable Net Income, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 136%, being 99% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	102,243
Cost of Goods Sold	1,803
Intangible Assets	0
Liabilities, Current	13,465
Liabilities, Non-Current	0
Other Assets	368
Other Compr. Net Income	0
Other Expenses	37,059
Other Liabilities	0
Other Net Income	1,648
Other Revenues	1,128
Property and Equipment	948
Research and Development	0
Selling, General and Administrative Expense	39,571

Output Variable	Value in 1000 USD
Assets	103,559
Liabilities	13,465
Expenses	78,433
Revenues	1,128
Stockholders Equity	90,094
Net Income	-75,657
Comprehensive Net Income	-75,657
Economic Capital Ratio	136%

